(Reuters) – ARS Pharmaceuticals said on Friday the European Medicines Agency (EMA) has recommended the approval of its needle-free emergency treatment, EURneffy, for allergic reactions.
EURneffy is seen as an alternative to EpiPen and other autoinjectors that are filled with epinephrine, a life-saving drug used by people at risk of anaphylaxis and other allergic reactions.
The U.S.-based ARS said the European Commission which usually follows the EMA’s recommendation, is expected to decide on EURneffy in the third quarter of 2024.
The nasal spray is also under review by the U.S. Food and Drug Administration, which is expected to decide on approval for the drug on Oct.2.
(Reporting by Christy Santhosh; Editing by Nivedita Bhattacharjee and Shailesh Kuber)
Comments